Tretinoin (Topical) for Melasma

Verdict: Published with Warning

Across 5 PubMed studies, the evidence for Tretinoin (Topical) in Melasma grades Tier A — moderate evidence. Effective, but with safety or population caveats.

A 🔵 A Moderate Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.74
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
87%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.75
L3 MechanismPlausibility
0.75
L5 Clinical bodiesAuthoritative stance
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.74
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review
PMID: 24438951 2014 Cochrane Review n = 2,125
Finding: Triple-combination cream containing tretinoin out-lightened hydroquinone alone (RR 1.58, 95% CI 1.26-1.97); tretinoin vs placebo showed significant objective severity reduction in both trials but participant-rated improvement reached significance in only one small trial (RR 13, 95% CI 1.88-89.74).
Academic Effect size: Triple combination vs HQ: RR 1.58 (95% CI 1.26-1.97); tretinoin monotherapy vs placebo (patient-rated, 1 trial): RR 13 (95% CI 1.88-89.74)
View on PubMed
Interventions for melasma
PMID: 20614435 2010 Cochrane Review n = 2,125
Finding: Same dataset as the 2014 abridged version: the tretinoin-containing triple combination beat hydroquinone alone (RR 1.58, 95% CI 1.26-1.97) and tretinoin reduced objective severity versus placebo, but the review concluded overall study quality was generally poor and available treatments inadequate.
Academic Effect size: Triple combination vs HQ: RR 1.58 (95% CI 1.26-1.97)
View on PubMed
Comparison of the Efficacy of Melasma Treatments: A Network Meta-Analysis of Randomized Controlled Trials
PMID: 34660626 2021 統合分析
Finding: Across 59 RCTs and 14 therapies, topical tretinoin monotherapy ranked only 11th of 14 for efficacy (lasers, IPL, triple-combination cream, topical vitamin C and oral tranexamic acid ranked higher), but tretinoin had the lowest side-effect rate at 10.1%.
Effect size: Efficacy rank 11/14 vs placebo; side-effect rate 10.1% (lowest of 14 therapies); no SUCRA/point estimate reported in abstract
View on PubMed
The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review
PMID: 19489658 2009 系統性回顧
Finding: Concluded there is fair (Grade B) evidence for topical tretinoin monotherapy in melasma and Grade B evidence for the fixed triple-combination (hydroquinone 4%/tretinoin 0.05%/fluocinolone 0.01%), while noting adverse effects (irritation, erythema, peeling) are frequent though mild-to-moderate.
Effect size: Grade B (fair evidence) for tretinoin monotherapy; Grade B for triple combination; no pooled quantitative estimate reported
View on PubMed
Melasma Treatment: An Evidence-Based Review
PMID: 31802394 2020 系統性回顧 n = 6,897
Finding: Across 113 studies (6897 participants) it concluded the tretinoin-containing triple-combination cream and hydroquinone monotherapy are the most effective and best-studied treatments, with chemical peels and lasers equal or inferior to topicals but carrying higher adverse-effect risk.
Effect size: Qualitative: triple combination (with tretinoin) + hydroquinone rated most effective; no pooled effect estimate reported
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
RETIN-A (tretinoin) is indicated for topical application in the treatment of acne vulgaris. RENOVA (tretinoin cream) 0.05% is indicated as an adjunctive agent for use in the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA DOES NOT ELIMINATE WRINKLES, REPA… source↗
L4b EU EFSA
Cautious
For topically applied retinoids (adapalene, alitretinoin, isotretinoin, tazarotene and tretinoin), systemic absorption is negligible, and unlikely to result in psychiatric disorders. ... topical retinoids must also not be used during pregnancy, and by women planning to have a baby. source↗
L4c UK NHS
Supportive
Tretinoin and adapalene are topical retinoids used to treat acne. They're available in a gel or cream and are usually applied once a day before you go to bed. Apply to all the parts of your face affected by acne 20 minutes after washing your face. Topical retinoids work by removing dead skin cells from the surface of the skin (exfoliating), which helps prevent them building up within hair folli… source↗
L4d TW TFDA / 衛福部
Supportive
外用A酸藥膏,僅新上市或濃度較高的製劑屬於處方藥,其他多數外用A酸,例如濃度不超過0.1%之Tretinoin,即為指示藥品,民眾可在諮詢藥師或醫師後,自行於藥局購買。衛生福利部食品藥物管理署建議,若是嚴重或大面積痤瘡,應尋求專科醫師診治;而輕度及小面積的痘痘,則可至藥局向藥師諮詢,再購買外用A酸指示藥品。 source↗
L4e WHO
Supportive
It is on the World Health Organization's List of Essential Medicines. [...] the compound received US Food and Drug Administration (FDA) approval for acne in 1971. [...] Use during pregnancy is contraindicated due to the risk of birth defects. [...] Tretinoin activates three members of the retinoic acid nuclear receptors (RARα, RARβ, and RARγ) which may act to modify gene expression, subsequent … source↗
L5a NIH Office of Dietary Supplements
Supportive
Tretinoin is indicated for topical application in the treatment of acne vulgaris. Rx only. HUMAN PRESCRIPTION DRUG LABEL. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin. The skin of certain sensitive individuals may become excessively red,… source↗
L5b Mayo Clinic
Supportive
Fluocinolone, hydroquinone, and tretinoin topical is a combination of medicines used to treat moderate to severe melasma (skin discoloration) of the face. Fluocinolone is a corticosteroid (steroid medicine), hydroquinone is a bleaching agent, and tretinoin is a retinoid (related to vitamin A). source↗
L5c Cleveland Clinic
Supportive
Tretinoin: This prescription is a topical retinoid. It's effective, but can cause dermatitis and should not be used during pregnancy. ... The combination of hydroquinone, tretinoin and a moderate topical steroid has had the best effect on melasma. source↗
L5d Harvard Health
Supportive
A common choice is the combination of hydroquinone with a retinoid that increases skin cell turnover and a steroid that decreases skin inflammation. source↗
L5e Specialty Society (condition-mapped)
Supportive
Tretinoin and a mild corticosteroid: This combination contains a retinoid and an anti-inflammatory, which can even out skin tone. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-melasma-INT-tretinoin-001 繁體中文版 →